To treat the EGFR-GBM, we can tag the mAbs to target other surface receptors overexpressed in GBM, such as PDGFR, TGF-βR, CXCR4, uPAR, and others as reported in the literature [43,44]. This evidence concerns the gene CXCR4 and glioblastoma.